Dr. Jeffrey Millman
@jeffreymillman.bsky.social
1.8K followers 3.5K following 120 posts
Washington University School of Medicine Professor | Diabetes Researcher | Stem Cell Biologist | Bioengineer | Inventor | STEM Educator | Former MIT & Harvard | Former Biotech VP | https://sites.wustl.edu/millmanlab/
Posts Media Videos Starter Packs
jeffreymillman.bsky.social
Overall, CVB3 sparks diverse, cell type-specific stress pathways in islets, with MIR7-3HG emerging as a regulator of infection + survival. These insights could help unravel viral contributions to T1D.
jeffreymillman.bsky.social
We also identified the lncRNA MIR7-3HG as a key player. Knockdown in stem cell-derived islets ↓ viral genome levels, ↓ apoptosis, and altered autophagy, suggesting new therapeutic angles.
jeffreymillman.bsky.social
CVB3 disrupted mitochondria differently across cell types. Beta cells had increased mitochondrial size but lose efficiency. Alpha cells had shrunken mitochondria. These are potentially protective acclimations.
jeffreymillman.bsky.social
Beta, alpha, and duct cells had the strongest responses. Beta and alpha cells demonstrated mitochondrial dysfunction. Duct had the strongest interferon & HLA responses. All cells had unique stress and immune signatures.
jeffreymillman.bsky.social
[please retweet] I’m #hiring! The Millman Lab is looking for a postdoctoral researcher to lead an exciting new project focused on vascularized #stemcell-derived islets for #diabetes disease modeling and cell replacement therapy. Email me your CV and cover letter.
jeffreymillman.bsky.social
Join us for the 2025 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium. We have an amazing program this year focusing on type 1 #diabetes. We have also extended the abstract submission deadline to Sept 19. Register and submit your abstract a www.levinesymposium.com
jeffreymillman.bsky.social
It has been a decade filled with challenges, breakthroughs, and the joy of discovery.

I cannot wait to see what the next ten years bring for my lab, my trainees, and the field of SC-islets.

Here’s to the next chapter. 🙌
jeffreymillman.bsky.social
I’m continually inspired by my interactions with people living with diabetes. Hearing your experiences reminds my team and me why our work matters and fuels our commitment to advancing SC-islet research. Your stories are the heart behind the science. Thank you!
jeffreymillman.bsky.social
I’m deeply grateful to WashU Medicine and the Division of Endocrinology for fostering an environment where collaboration and innovation thrive.

Thanks also to @breakthrought1dhq.bsky.social, NIH NIDDK, and generous philanthropic donors for supporting our work.
jeffreymillman.bsky.social
None of this would have been possible without the people in my lab, 41 trainees so far. Mentoring them has been a privilege, and many have gone on to accomplish great things in academia and industry. Their success is one of the most rewarding parts of my career.
jeffreymillman.bsky.social
SC-islets are now widely used around the world to study human development, model disease, and advance cell replacement therapies.

It has been remarkable to see this area of research explode since we reported them in 2014 to become a cornerstone of diabetes science.
jeffreymillman.bsky.social
The field has also made huge leaps this past decade.

Vertex reported groundbreaking clinical trial results with SC-islets, and Sana Biotechnology has successes with hypoimmune islets, showing potential for cell therapy without chronic immunosuppression.
jeffreymillman.bsky.social
Along the way, we developed new genetic and microenvironmental models to study pancreatic islet biology and uncovered how stem cells decide to become islets and revealed new aspects of the disease state of beta cells, guiding future therapeutic strategies.
jeffreymillman.bsky.social
We generated SC-islets from patients with T1D, enabling patient-specific disease modeling.

We also used gene editing to repair the Wolfram syndrome mutation in patient-derived SC-islets, a step toward precision medicine in rare forms of diabetes.
jeffreymillman.bsky.social
Over the past 10 years, my lab has worked to advance stem cell–derived islets (SC-islets) for diabetes research and treatment.

We created SC-islets effective in vivo, bringing us closer to a functional cure for type 1 diabetes (T1D).
jeffreymillman.bsky.social
A few days ago marked my 10th anniversary as a faculty member at Washington University School of Medicine in St. Louis.

I arrived in 2015 as an Assistant Professor, excited but nervous to start my own lab.

Today, I’m a Full Professor, reflecting on an incredible decade. 🧵
jeffreymillman.bsky.social
New application note from R&D Systems showcases efficient, reproducible generation of iPSC-derived pancreatic islets based on our 2021 Nature Protocols paper. High purity (75–80% C-peptide+/NKX6.1+) & robust glucose-stimulated insulin secretion www.rndsystems.com/resources/li... #T1D
www.rndsystems.com
jeffreymillman.bsky.social
When you say yes to just one more committee and now you're chairing it
jeffreymillman.bsky.social
Meet Allison Kelley, a technician at WashU’s Millman Lab! A Biomedical Engineering grad from UMiami, she authored a new paper in Biotechnology & Bioengineering and is shaping her career at the intersection of science, medicine, and patent law #womeninSTEM sites.wustl.edu/millmanlab/p...
Meet the Researcher: Allison Kelley
By Erika Brown – July 7, 2025 Research Technicians are the backbone of research laboratories. They actively participate in various projects, acquiring knowledge that they can apply in their f…
sites.wustl.edu